Leukemia Clinical Trials in Georgia

Showing 801-820 of 1,393 trials

P3 (Prepared, Protected, emPowered)

NCT03320512

P3 (Prepared, Protected, emPowered) is an interactive smartphone app for HIV-uninfected YMSM and YTW that utilizes social networking and game-based mechanics as well as a comprehensive understanding of what constitutes "best practices" in app development to improve PrEP adherence and persistence in PrEP care.

Sexually Transmitted DiseasesSafe SexAdherence, Medication

University of North Carolina, Chapel Hill246 participantsStarted May 2019

Tampa, Florida, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +6 more locations

TERMINATEDPhase 165 miles

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

NCT03218683

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies Part 1 of the study is monotherapy dose escalation. Closed November 2020 Part 2 of the study is monotherapy expansion groups for relapsed/refractory chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM). Closed November 2020 Part 3 is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in subjects with relapsed/refractory AML

Relapsed or Refractory Acute Myeloid Leukemia (AML)

AstraZeneca70 participantsStarted Aug 2017

Orange, California, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +7 more locations

PreviousPage 41 of 70Next

P3 (Prepared, Protected, emPowered)

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Leukemia Trials in Other Cities

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

A Study of PLX2853 in Advanced Malignancies.

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Other Conditions in Georgia